Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.66 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.66 |
| ▸ | ITGAL | P20701 | 20/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169786 | 1.00 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL12054500 | 1.00 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4921783 | 1.00 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL19158618 | 1.00 | ITGB2 (0.66) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL16727763 | 0.94 | ITGB2 (0.58) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL16851515 | 0.93 | ITGB2 (0.57) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL17991452 | 0.90 | ITGB2 (0.71) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL12169840 | 0.90 | ITGB2 (0.71) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL4756011 | 0.90 | ITGB2 (0.71) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL18885220 | 0.89 | ITGB2 (0.71) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | NOVARTIS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-8168655-B2 | Compositions and methods for treatment of eye disorders | SARCODE BIOSCIENCE INC. (US) | 2012-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10960087-B2 | Compositions and methods for treatment of diabetic retinopathy | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20210338839-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
| US-20160220702-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | VCAM1, ITGB1, ICAM1 | ITGB2 11/4885ICAM1 3/4885ITGAL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.